Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 88.09B |
| Revenue (ttm) | 46.65B |
| Net Income (ttm) | -8.64B |
| Shares Out | n/a |
| EPS (ttm) | -4.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 2.26 (5.19%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 690 |
| Average Volume | 1,506 |
| Open | 43.61 |
| Previous Close | 43.88 |
| Day's Range | 43.50 - 44.00 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | 0.41 |
| RSI | 25.43 |
| Earnings Date | Apr 24, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol-Myers Squibb (BMY) Shares Decline Amid FDA Updates and Mixed Trial Results
Bristol-Myers Squibb (BMY) Shares Decline Amid FDA Updates and Mixed Trial Results
Bristol-Myers Squibb Co (BMY) Announces FDA Updates for CAMZYOS Prescribing Information | BMY ...
Bristol-Myers Squibb Co (BMY) Announces FDA Updates for CAMZYOS Prescribing Information | BMY stock news
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsu...
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol...
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch
In March this year, U.S. pharma giant Eli Lilly And Co (NYSE: LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest p...
Optellum partners with Bristol Myers to use AI-driven lung cancer diagnosis
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.
Bristol Myers fails in late-stage trial of hypertrophic cardiomyopathy treatment
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) cl...
Bristol Myers gets FDA approval for Opdivo, Yervoy combination in liver cancer
U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adult patients with...
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face t...
Cipla in focus after USFDA approves generic version of blockbuster cancer drug Abraxane
Shares of Cipla Limited rose as much as 3.55% to ₹1,465.90 in early trade on Friday, following the company’s announcement that it has received final approval from the US Food and Drug Administration (...
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric pa...
Bristol-Myers gets Pomalyst antitrust case dismissed
Bristol Myers gets FDA approval for Opdivo, Yervoy combination in colorectal cancer
U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
Don't overlook the impact of pharma tariffs, says an analyst. Where we stand on Bristol Myers
The drug stock is higher over the past month while the S&P 500 has pulled back sharply.
Bristol-Myers Squibb (BMY) Among Cramer's Top Pharmaceutical Picks
Bristol-Myers Squibb (BMY) Among Cramer's Top Pharmaceutical Picks